Eli Lilly and Co (NYSE:LLY) shares are 2.34% higher this morning after the drug company updated its 2015 EPS guidance to between $2.28 and $2.33 from the previous range of $2.40 – $2.45 due to tax charges related to a rights acquisition. The company also issued bullish 2016 outlook for EPS of $2.92 – $3.02 and revenues between $20.2 billion and $20.7 billion. A total of 47 funds from our database owned Eli Lilly and Co (NYSE:LLY) as of September 30. That's up four funds from the previous quarter.